Noscira Initiates Phase II Clinical Trials With NP 12, Its First Drug For Alzheimer’s Disease

Noscira, a company of Zeltia group devoted to the research and development of innovative drugs for the treatment of diseases of the nervous system, has received the approval of the Austrian health authorities and the Ethics Committee for the initiation of the first Phase II study with NP-12 for the treatment of Alzheimer’s disease. NP-12, the first compound of Noscira’s product pipeline, is an innovative drug of a new family of compounds.

More: continued here

Filed under: Alzheimer's / Dementia News XML/RSS Feed on October 28th, 2008